Advisory Panel on COVID-19 Vaccines convenes meeting to conduct continuous benefit-risk analysis of authorised COVID-19 vaccines

     The Advisory Panel on COVID-19 Vaccines (Advisory Panel) convened a meeting today (September 19) to conduct continuous benefit-risk analysis of the authorised COVID-19 vaccines. The meeting was chaired by convenor Professor Wallace Lau Chak-sing.

     At the meeting today, the Advisory Panel reviewed the continuous benefit-risk balance of the two authorised vaccines. After reviewing all the latest clinical information, real-world data on efficacy and safety related to the Comirnaty and Sinovac vaccines (including safety reports submitted by the authorisation applicants), the Advisory Panel considered that there was no new significant safety signal identified, though continuous monitoring was still required. The quality of the Comirnaty and Sinovac vaccines imported has already passed the certification and appropriate testing for quality control. In summary, the Advisory Panel still considered that the benefits of the two vaccines outweighed the risks, and that there was no need to recommend changes regarding the use of the two vaccines.

     The Advisory Panel will submit the relevant views to the Secretary for Health for consideration. The information concerned will be uploaded to the website of the Health Bureau later on.

     "The Government will continue to ensure that the authorised vaccines satisfy the criteria of safety, efficacy and quality, and disseminate the latest safety and scientific information on the relevant vaccines to the public and relevant stakeholders in a timely manner," a Government spokesman said.

     The Comirnaty vaccine and Sinovac vaccine were authorised in accordance with the Prevention and Control of Disease (Use of Vaccines) Regulation (Cap. 599K) on January 25 and February 18, 2021, respectively. To comply with the conditions of authorisation, the authorisation applicants are required to submit the latest clinical data on the vaccines, safety update reports and quality certification documents, etc for continuous review and monitoring.

Ends/Monday, September 19, 2022
Issued at HKT 18:08